ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir
Drug: Placebo

First Posted Date: 2017-07-19

Last Posted Date: 2019-12-23

Lead Sponsor: AbbVie

Target Recruit Count: 546

Registration Number: NCT03222583

Locations: 🇨🇳
The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156900, Guangzhou, Guangdong, China
🇨🇳
Xiangya Hospital Central South University /ID# 156901, Changsha, Hunan, China
🇨🇳
Jiangsu Province People's Hospital /ID# 156861, Nanjing, Jiangsu, China

and more 45 locations

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Completed

Conditions: Rheumatoid Arthritis (RA)
Non-radiographic Axial Spondyloarthritis
Ankylosing Spondylitis (AS)
Crohn's Disease
Ulcerative Colitis (UC)
Psoriatic Arthritis
Psoriasis

First Posted Date: 2017-07-19

Last Posted Date: 2020-02-24

Lead Sponsor: AbbVie

Target Recruit Count: 116

Registration Number: NCT03223012

Locations: 🇵🇹
Instituto Portugues De Reumatologia /ID# 205963, Lisbon, Lisboa, Portugal
🇵🇹
CCA Braga - Hospital de Braga /ID# 201323, Braga, Portugal
🇵🇹
Centro Hosp de Tondela-Viseu /ID# 203775, Viseu, Portugal

and more 12 locations

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-07-17

Last Posted Date: 2020-03-17

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT03219216

Locations: 🇧🇷
Hospital de Clinicas de Porto Alegre /ID# 163167, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Ernesto Dornelles /ID# 163171, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital de Clinicas de Porto Alegre /ID# 163166, Porto Alegre, Rio Grande Do Sul, Brazil

and more 11 locations

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: methotrexate
Drug: risankizumab

First Posted Date: 2017-07-17

Last Posted Date: 2022-11-03

Lead Sponsor: AbbVie

Target Recruit Count: 104

Registration Number: NCT03219437

Locations: 🇧🇷
CETI - Centro de Estudos em Terapias Inovadoras /ID# 208593, Curitiba, Parana, Brazil
🇧🇷
PUC Trials-Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR /ID# 164401, Curitiba, Parana, Brazil
🇧🇷
Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 164743, Botucatu, Sao Paulo, Brazil

and more 8 locations

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-07-11

Last Posted Date: 2019-09-04

Lead Sponsor: AbbVie

Target Recruit Count: 230

Registration Number: NCT03212521

Locations: 🇺🇸
Univ Maryland School Medicine /ID# 161157, Baltimore, Maryland, United States
🇺🇸
Digestive Disease Associates - Baltimore /ID# 161260, Baltimore, Maryland, United States
🇺🇸
University of Vermont Medical Center /ID# 161263, Burlington, Vermont, United States

and more 39 locations

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: Estradiol/Norethindrone Acetate
Drug: Placebo for Elagolix
Drug: Elagolix
Drug: Placebo for E2/NETA

First Posted Date: 2017-07-11

Last Posted Date: 2024-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 681

Registration Number: NCT03213457

Locations: 🇺🇸
Clinical Research Adv, Inc. /ID# 149257, Puyallup, Washington, United States
🇺🇸
Tidewater Clinical Research /ID# 145397, Virginia Beach, Virginia, United States
🇺🇸
Atlanta Women's Research Inst /ID# 145543, Atlanta, Georgia, United States

and more 194 locations

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2017-06-28

Last Posted Date: 2020-10-08

Lead Sponsor: AbbVie

Target Recruit Count: 505

Registration Number: NCT03201718

Locations: 🇰🇷
Kyungpook National Univ Hosp /ID# 168731, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
Dong-A University Hospital /ID# 167362, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷
Yeungnam University Med Ctr /ID# 167425, Daegu, Daegu Gwang Yeogsi, Korea, Republic of

and more 56 locations

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Navitoclax
Drug: Chemotherapy
Drug: Venetoclax

First Posted Date: 2017-06-08

Last Posted Date: 2021-10-14

Lead Sponsor: AbbVie

Target Recruit Count: 69

Registration Number: NCT03181126

Locations: 🇺🇸
City of Hope /ID# 169029, Duarte, California, United States
🇺🇸
LPCH Stanford /ID# 163337, Palo Alto, California, United States
🇺🇸
University of Chicago /ID# 163369, Chicago, Illinois, United States

and more 12 locations

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Phase 2

Completed

Conditions: Ankylosing Spondylitis (AS)

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2017-06-07

Last Posted Date: 2023-03-07

Lead Sponsor: AbbVie

Target Recruit Count: 187

Registration Number: NCT03178487

Locations: 🇸🇪
Reumatologkliniken /ID# 165713, Vaesteras, Sweden
🇺🇸
Bay Area Arthritis and Osteo /ID# 165023, Brandon, Florida, United States
🇺🇸
St. Lukes Clinic /ID# 165827, Meridian, Idaho, United States

and more 98 locations

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

Completed

Conditions: Uveitis

First Posted Date: 2017-05-16

Last Posted Date: 2021-02-11

Lead Sponsor: AbbVie

Target Recruit Count: 155

Registration Number: NCT03155243

Locations: 🇦🇹
Medizinische Universität Graz /ID# 206301, Graz, Steiermark, Austria
🇦🇹
Medical University of Vienna /ID# 206190, Vienna, Wien, Austria
🇨🇴
Clinica Oftalmologica del Caribe /ID# 206448, Barranquilla, Atlantico, Colombia

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy